Mass Spectrometry in the Hit to Lead phase of drug discovery: Applications today and options for tomorrow

Tue2  Sep04:00pm(30 mins)
Charter 1
 Jonathan Wingfield


The direct label free measurement of substrate to product conversion in both biochemical and cellular assays is probably considered the "Holy Grail" of screening. Mass Spectrometry has the potential to be the end point of this particular quest. This presentation will review current applications of MS screening within early drug discovery at AstraZeneca and share case study data to demonstrate the impact of MS screening. AZ is looking to new technologies which offer potential solutions to the current challenges of using MS as a screening end point. In particular, applications for MALDI and other soft ionisation techniques and the use of acoustic technology to address throughput bottlenecks.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021